<DOC>
	<DOCNO>NCT00602030</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy SNDX-275 combination erlotinib treatment Advanced Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>Study Evaluate Erlotinib With Without SNDX-275 Treatment Patients With Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion Criteria Cytologically histologically confirm NSCLC stage IIIb IV Received least 1 2 prior chemotherapy chemoradiotherapy regimen advance NSCLC ( include erlotinib valporic acid ) progress base radiologic evidence At least 1 measurable lesion conventional spiral CT scan ECOG performance score 0 , 1 , 2 life expectancy least 6 month Paraffinembedded tumor specimen available correlative study Male female 18 year age Hemoglobin ≥ 9.0 g/dL ; platelet ≥ 100 x 109/L ; ANC ≥ 1.5 x 109/L without use hematopoietic growth factor Bilirubin creatinine less 2 time upper limit normal institution Albumin ≥ 2.5 /dL AST ALT less 3 time upper limit normal institution Prothrombin time le 1.5 time upper limit normal institution Potassium , magnesium phosphorus within normal range institution ( supplementation permissible ) Willing use accept effective method contraception study ( men woman appropriate ) 3 month last dose SNDX275 Patient legally acceptable representative grant write informed consent studyspecific procedure ( include special screening test ) perform Exclusion Criteria Prior stem cell transplant Clinical evidence CNS involvement Prior treatment HDAC inhibitor EGFR inhibitor Currently take know inhibitor CYPA4 , include limited atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , troleandomycin , ≥ 10 mg prednisone , voriconazole Current use valporic acid Prior exposure SNDX275 Systemic chemotherapy , radiotherapy , treatment investigational agent without recovery least grade 1 baseline study drug administration Daily treatment ≥ 10 mg prednisone within 28 day study drug administration Local whole brain palliative radiotherapy within 14 day study drug administration Currently active second malignancy , malignancy within last 5 year cure basal squamous cell skin carcinoma , cervical carcinoma situ , carcinoma situ bladder , papillary thyroid cancer Inability swallow oral medication gastrointestinal malabsorption condition Acute infection require IV antibiotic , antiviral , antifungal within 14 day study drug administration Known HIV infection , active hepatitis B C infection Another serious uncontrolled medical condition within 90 day study drug administration acute myocardial infarction , angina , ventricular arrhythmia , hypertension , diabetes mellitus , renal hepatic insufficiency Known hypersensitivity benzamides Women currently pregnant breastfeed Patient currently enrol ( complete within 28 day study drug administration ) another investigational drug study Patient kind medical , psychiatric , behavioral disorder place patient increase risk study participation compromise ability patient give write informed consent and/or comply study procedure requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>lung neoplasm</keyword>
	<keyword>respiratory</keyword>
</DOC>